Sotrovimab lost neutralization efficacy against SARS-CoV-2 subvariants but remained clinically effective: Were monoclonal antibodies against COVID-19 rejected too early?

Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

3 Downloads (Pure)
OriginalsprogEngelsk
Artikelnummer102512
TidsskriftJournal of Infection and Public Health
Vol/bind17
Udgave nummer9
ISSN1876-0341
DOI
StatusUdgivet - sep. 2024

Citationsformater